Comparative Pharmacology
Head-to-head clinical analysis: DHIVY versus NORETHIN 1 50M 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DHIVY versus NORETHIN 1 50M 28.
DHIVY vs NORETHIN 1/50M-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Norethindrone is a synthetic progestin that binds to the progesterone receptor, suppressing gonadotropin release and inhibiting ovulation. Estradiol provides negative feedback on the pituitary to reduce FSH and LH secretion, preventing follicular development.
DHIVY is not a recognized drug. No dosing information available.
One tablet orally once daily for 28 consecutive days per menstrual cycle. Each tablet contains 1 mg norethindrone and 50 mcg ethinyl estradiol.
None Documented
None Documented
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when CrCl <30 mL/min).
The terminal elimination half-life of norethindrone is approximately 7-8 hours following oral administration. Steady-state concentrations are achieved within 5-7 days. The half-life may be prolonged in patients with hepatic impairment.
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Norethindrone (NET) and its metabolites are primarily excreted via the kidneys (50-70%) and feces (20-40%) as glucuronide and sulfate conjugates. Approximately 30-50% of an oral dose is recovered in urine within 24 hours, with extensive enterohepatic recirculation prolonging elimination.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive